论文部分内容阅读
作者以 VENP 方案作为初期缓解诱导治疗了13例急性淋巴细胞白血病(ALL),患者年龄14～67岁(中值年龄31岁),男6例,女7例。长春新碱(VCR)1或2mg 静注/周;环磷酰胺(Ex)50～100mg/日口服或200～500mg×2/周静注;NAT(甲基苄肼)50～100mg/日口服;强的松龙20～30mg/日口服。各药剂量根据每个病例的具体情况决定。如骨髓白血病细胞小于5%,血液白血病细胞消失为完全缓解;病程中骨髓白血病细胞大于5%或血像中又见白血病细胞出现则为复发,生存期从开始应用化疗时计算。结果9例完全缓解,1例部份缓解,3例无效。
Thirteen patients with acute lymphoblastic leukemia (ALL) were treated with VENP as initial remission induction therapy. The patients ranged in age from 14 to 67 years (median age, 31 years), 6 males and 7 females. Vincristine (VCR) 1 or 2 mg iv / week; cyclophosphamide (Ex) 50-100 mg / day orally or 200-500 mg x 2 / week intravenous; NAT (procarbazine) 50-100 mg / day orally ; Prednisolone 20 ~ 30mg / day oral. The dosage of each medicine is decided according to the specific situation of each case. Such as less than 5% of myeloid leukemia cells, complete disappearance of blood leukemia cells; more than 5% of myeloid leukemia cells in the course of the disease or leukemia cells in the blood, see the recurrence, the survival time from the beginning of chemotherapy. Results 9 cases were completely relieved, 1 case partially relieved, 3 cases ineffective.